Recently, in the search for new drugs to inhibit pro-inflammatory adipokine secretion in type 2 diabetes patients, emerging evidence has identified that the CXCR1/2 inhibitor ladarixin could enhance insulin resistance in 3T3-L1 adipocytes by reducing inflammation and improving insulin signaling (16). The gene discussed is INS; the disease is type 2 diabetes mellitus.